Androgen receptor abnormalities by Brinkmann, A.O. (Albert) et al.
J. Steroid Biochem. Molec. Biol. Vol. 40, No. 1-3, pp. 349-352, 1991 0960-0760/91 $3.00 + 0.00 
Prihted in Great Britain. All rights reserved Copyright © 1991 Pergamon Press plc 
Steroid Receptor and Enzyme Abnormalities 
ANDROGEN RECEPTOR ABNORMALITIES 
A. O. BRINKMANN, I* G. G. J. M. KUIPER, I C. RIS-STALPERS, l H. C. J. VAN ROOIJ, 2 
G. ROMALO, 3 M. TRIFIRO, 4 E. MULDER, l L. PINSKY, 4 H. U. SCHWEIKERT 3 
and J. TRAPMAN 2 
Departments of tBiochemistry II and 2pathology, Erasmus University, P.O. Box 1738, 3000 DR 
Rotterdam, The Netherlands, 3Department of Internal Medicine, University of Bonn, Germany and 4Lady 
Davis Institute, McGill University, Montreal, Canada 
Summary--The human androgen receptor is a member of the superfamily of steroid hormone 
receptors. Proper functioning of this protein is a prerequisite for normal male sexual 
differentiation and development. The cloning of the human androgen receptor cDNA and the 
elucidation of the genomic organization of the corresponding gene has enabled us to study 
androgen receptors in subjects with the clinical manifestation fandrogen insensitivity and in 
a human prostate carcinoma cell line (LNCaP). Using PCR amplification, subcloning and 
sequencing of exons 2-8, we identified a G -~ T mutation in the androgen receptor gene of a 
subject with the complete form of androgen insensitivity, which inactivates the splice donor 
site at the exon 4/intron 4 boundary. This mutation causes the activation of a cryptic splice 
donor site in exon 4, which results in the deletion of 41 amino acids from the steroid binding 
domain. In two other independently arising cases we identified two different nucleotide 
alterations in codon 686 (GAC; aspartic acid) located in exon 4. One mutation (G ~ C) results 
in an aspartic acid-~ histidine substitution (with negligible androgen binding), whereas the 
other mutation (G --* A) leads to an aspartic acid ~ asparagine substitution ( ormal androgen 
binding, but a rapidly dissociating androgen receptor complex). Sequence analysis of the 
androgen receptor in human LNCaP-cells (lymph node carcinoma of the prostate) revealed 
a point mutation (A ~ G) in codon 868 in exon 8 resulting in the substitution of threonine 
by alanine. This mutation is the cause of the altered steroid binding specificity of the 
LNCaP-cell androgen receptor. The functional consequences of the observed mutations with 
respect o protein expression, specific ligand binding and transcriptional ctivation, were 
established after transient expression of the mutant receptors in COS and HeLa cells. These 
findings illustrate that functional errors in the human androgen receptor have an enormous 
impact on phenotype and fertility. 
INTRODUCTION 
Androgens (e.g. testosterone and 5~t-dihy- 
drotestosterone) are indispensable for normal 
male sexual differentiation. Androgen action at 
the target cell level is accomplished via a low 
abundance nuclear protein: the androgen re- 
ceptor. The androgen receptor belongs to the 
steroid/thyroid hormone/retinoic acid receptor 
family [1, 2]. 
It is generally accepted that in the X-chromo- 
some linked androgen insensitivity syndrome 
defects in the androgen receptor gene have 
prevented the normal development of both in- 
ternal and external male structures in 46, XY 
individuals [3, 4]. The recent cloning and 
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characterization f cDNA encoding the human 
androgen receptor and the elucidation of the 
organization of the human androgen receptor 
gene have greatly increased our knowledge of 
the molecular structure of the human androgen 
receptor [5-9]. The information on the molecu- 
lar structure of the human androgen receptor 
has facilitated the study of molecular defects 
associated with androgen insensitivity [10-15]. 
Moreover, naturally occurring mutations in the 
androgen receptor are a potentially interesting 
source for the investigation of receptor struc- 
ture-function relationships. In addition, the 
variation in clinical syndromes provides the 
opportunity to correlate a mutation in the an- 
drogen receptor structure with the impairment 
of a specific physiological function of the andro- 
gen receptor. In the present investigation the 
molecular structure of the human androgen 
receptor was analysed after amplification by 
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PCR and subsequent sequencing of the individ- 
ual exons of the androgen receptor gene from 
three different subjects with the complete form 
of androgen insensitivity and from a human 
prostate cancer cell line (LNCaP). 
PRIMARY STRUCTURE OF THE HUMAN 
ANDROGEN RECEPTOR 
The primary structure of the human andro- 
gen receptor has been determined after mol- 
ecular cloning and characterization f cDNA 
encoding the human androgen receptor [7, 8]. 
The cDNA sequence reveals an open reading 
frame of 2730 nucleotides encoding a protein 
of 910 amino acid residues with a calculated 
molecular mass of 98,500 Da. 
STRUCTURAL ORGANIZATION OF THE HUMAN 
ANDROGEN RECEPTOR GENE 
The human androgen receptor gene is located 
on the X-chromosome and has a length of 
> 90 kb [9, 16, 17]. The information for the pro- 
tein-coding region is separated over 8 exons 
(Fig. 1). The sequence ncoding the N-terminal 
domain is present in 1 large exon (exon 1)[8]. 
The DNA-binding domain is encoded by exons 
2 and 3, and the information for the steroid- 
binding domain is distributed over 5 exons 
(exons 4-8) [9]. 
ANALYSIS OF GENOMIC DNA OF SUBJECTS 
WITH ANDROGEN INSENSITIVITY 
A mutation in the intron 4 splice donor site 
Examination by Southern blotting of 
genomic DNA isolated from genital skin 
fibroblasts of a subject (index patient 20.1) 
with complete androgen insensitivity and no 
detectable androgen binding to receptors in 
target cells revealed the presence of the complete 
androgen receptor gene. 
To investigate whether a point mutation or 
small gene deletion was responsible for the 
absence of hormone binding in genital skin 
fibroblasts of this patient's exons 4-8, coding for 
the steroid-binding domain of the androgen 
receptor were amplified from genomic DNA 
using the polymerase chain reaction. In ad- 
dition, exons 2 and 3, coding for the DNA-bind- 
ing domain were amplified. Exons 2-8 and all 
corresponding exon/intron junctions were se- 
quenced. Sequences were found to be identical 
to the previously published wild-type sequence 
with one exception: a G ~ T mutation on pos- 
ition 1 in the splice donor site of intron 4. 
The consequence of this point mutation on 
RNA-splicing was investigated after amplifica- 
tion of cDNA from subject 20.1 using specific 
primers for exons 4 and 5. This resulted in the 
identification of a mutant fragment, which 
was shorter than the corresponding fragment 
from the wild-type androgen receptor. This 
finding indicated an abnormal androgen recep- 
tor mRNA-splicing. Sequence analysis of the 
mutant fragment revealed the use of a cryptic 
splice donor site CAG/GTGTAG at position 
2020/2021 in exon 4 of the human androgen 
receptor gene which is normally inactive. The 
use of this cryptic splice site results in the 
deletion of 123 nucleotides from the mRNA. 
Translation will consequently result in an in- 
frame deletion of 41 amino acid residues in the 
androgen receptor protein from this patient (see 
Fig. 2). 
Transient expression of the mutant androgen 
receptor in COS cells resulted in a protein which 
was approx. 5 kDa smaller than the wild-type 
receptor. The mutant receptor was unable to 
bind androgens and did not activate transcrip- 
tion of an androgen-regulated MMTV-CAT 
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Fig. 1. Structural organization ofthe human androgen receptor gene. The 8 exons of the human androgen 
receptor gene are numbered 1-8 and their corresponding position in the human androgen receptor cDNA 
is indicated together with the location of the N-terminal, DNA-binding and steroid-binding domains, 
respectively. 
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Fig. 2. Position of the deletion of amino acid residues 
674-714 in the human androgen receptor protein of patient 
20.1 as a result of an activation of a cryptic splice donor 
site in exon 4 due to a point mutation on position 1 of 
intron 4. 
reporter gene construct (in the presence as well 
as absence of ligand). The deletion of 41 amino 
acid residues is partly located in a region that 
displays a high degree of sequence conservation 
in the family of steroid hormone receptors and 
is supposed to be involved in the transduction f
the signal of hormone binding into derepression 
of receptor function [18]. 
Mutations of codon 686 in exon 4 
In two unrelated patients with the complete 
form of androgen insensitivity, two different 
point mutations were found at the same nucleo- 
tide in codon 686 (aspartic acid) of exon 4 
located in the steroid-binding domain (Fig. 3). 
Aspartic acid 686 is conserved in the steroid- 
binding domain of the progesterone, glucocorti- 
coid and mineralocorticoid receptor. Both mu- 
tations eliminate a HinfI restriction site (Fig. 3). 
One mutation (G ~ C) results in an aspartic 
acid ~ histidine substitution. In this patient he 
androgen receptor displays low to negligible 
androgen binding. The other mutation (G ~ A) 
leads to an aspartic acid ~ asparagine substi- 
tution. The androgen receptor in the patient 
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Fig. 3. Location of  the G ~ C and G ~ A substitutions at 
codon 686 in exon 4 of the human androgen receptor of 2 
subjects with the complete form of androgen insensitivity. 
The HinfI site of exon 4 is underlined. 
with the latter mutation shows normal androgen 
binding but the half-life of the androgen recep- 
tor complex is 5 times shorter than of the 
wild-type androgen receptor complex. 
Both mutant androgen receptors were transi- 
ently expressed in COS cells and displayed the 
same altered binding characteristics a  those 
measured in genital skin fibroblasts from the 
affected subjects. In co-transfections in HeLa 
cells using a GRE-tk-CAT reporter gene con- 
struct both mutant receptors were tested for 
their transcription activation activity. A partial 
activation of transcription (approx. 30%) was 
observed only in the presence of a 100-fold 
higher concentration of ligand as compared 
with the wild-type androgen receptor. Both 
mutant receptors were devoid of any transcrip- 
tional activation activity in the presence of 
physiological hormone concentrations. 
ANALYSIS OF GENOMIC DNA OF THE LNCaP 
CELL LINE 
Previous tudies have established that human 
LNCaP-cells can be stimulated with respect o 
growth by androgens, but surprisingly also by 
progesterone, R5020 (a synthetic progestagen) 
and oestradiol [19]. Characterization f the an- 
drogen receptor in these cells revealed an altered 
steroid-binding specificity with an increased 
preference for progestagens and oestradiol as 
compared with the steroid-binding specificity of 
the androgen receptor in normal cells[20]. 
These data strongly suggested a modification of 
the androgen receptor and particularly in the 
steroid-binding domain. To establish a possible 
small deletion or point mutation exons 2-8 of 
the LNCaP-cell androgen receptor were 
sequenced with the same approach as applied 
for the genomic DNA analysis of patients 
with androgen insensitivity. Sequence analysis 
revealed one point mutation in codon 
868 (threonine) in exon 8 located at the C- 
terminal end of the steroid-binding domain 
(Fig. 4). The mutation (A-* G) resulted in a 
threonine ~ alanine substitution. To determine 
whether the substitution affects the functional 
properties of the LNCaP androgen receptor the 
mutant eDNA was cloned in an expression 
vector and transiently expressed in COS-1 cells 
(for studying binding characteristics) and in 
HeLa cells (for studying transcription acti- 
vation of the reporter gene construct: GRE-tk- 
CAT). In the transfection studies the mutant 
receptor displayed increased binding affinity for 
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Fig. 4. Location of the point mutation (A --* G) in codon 
686 of exon 8 of the androgen receptor gene in human 
LNCaP-cells. The mutation results in the substitution of 
threonine by alanine in the C-terminal part of the hormone- 
binding domain. 
p rogestagens  and  oestradio l .  In  add i t ion ,  these 
l igands act ivate  t ranscr ip t ion  at  concent ra t ions  
wh ich  are inact ive  wi th  the wi ld - type androgen 
receptor .  These  results  conf i rm that  the ob-  
served po in t  mutat ion  in the LNCaP androgen 
receptors  the cause o f  the broad  s tero id -b ind ing  
specificity. Whether  this po in t  mutat ion  can  
p lay a role in progress ive  pros ta te  tumour  
growth  remains  to be establ ished.  
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